Science 37 Holdings, Inc. (NASDAQ:SNCE) Short Interest Update

Science 37 Holdings, Inc. (NASDAQ:SNCE) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 1,130,000 shares, a decrease of 22.6% from the August 15th total of 1,460,000 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is presently 0.7 days.

Science 37 Trading Up 6.4 %

SNCE opened at $0.33 on Monday. The stock has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.28. The company has a market cap of $38.65 million, a price-to-earnings ratio of -0.29 and a beta of 1.27. Science 37 has a 12-month low of $0.19 and a 12-month high of $1.99.

Science 37 (NASDAQ:SNCE) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter. Science 37 had a negative return on equity of 77.11% and a negative net margin of 217.87%. The firm had revenue of $15.35 million during the quarter, compared to the consensus estimate of $11.00 million.

Institutional Investors Weigh In On Science 37

A number of institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Science 37 in the second quarter worth $73,000. Goldman Sachs Group Inc. boosted its position in shares of Science 37 by 63.2% during the second quarter. Goldman Sachs Group Inc. now owns 328,849 shares of the company’s stock valued at $70,000 after buying an additional 127,338 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Science 37 by 68.9% during the second quarter. Renaissance Technologies LLC now owns 645,300 shares of the company’s stock valued at $137,000 after buying an additional 263,213 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of Science 37 during the second quarter valued at $137,000. Finally, Alyeska Investment Group L.P. boosted its position in shares of Science 37 by 20.5% during the first quarter. Alyeska Investment Group L.P. now owns 1,766,384 shares of the company’s stock valued at $497,000 after buying an additional 300,000 shares during the last quarter. 40.67% of the stock is owned by hedge funds and other institutional investors.

Science 37 Company Profile

Science 37 Holdings, Inc engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data.